Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  1999-12-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/JAMA.282.22.2104PMID 10591317
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

  1999cited by this paper
• In vitro correlate of immunity in an animal model of inhalational anthrax

  1999cited by this paper
• Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys

  1996cited by this paper
• Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.

  1996cited by this paper
• Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs.

  1995cited by this paper
• Pathology of experimental inhalation anthrax in the rhesus monkey.

  1995cited by this paper
• Efficacy of a standard human anthrax vaccine against Bacillus anthracis spore challenge in guinea-pigs.

  1994cited by this paper
• Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants

  1992cited by this paper
• Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity

  1986cited by this paper
• Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig

  1986cited by this paper
• Field Evaluation of a Human Anthrax Vaccine.

  1962cited by this paper
• Studies on immunity in anthrax. VI. Immunizing activity of protective antigen against various strains of Bacillus anthracis.

  1955cited by this paper

• Detoxification Techniques for Bacterial Toxins: A Pathway to Effective Toxoid Vaccines.

  2025cites this paper
• A Hierarchy of Medical Countermeasures Against Biological Threats.

  2022cites this paper
• Characterization of Bacillus anthracis Spore Proteins Using a Nanoscaffold Vaccine Platform

  2020cites this paper
• Review: The risk of contracting anthrax from spore-contaminated soil – A military medical perspective

  2020cites this paper
• Chapter 27 MEDICAL COUNTERMEASURES

  2018cites this paper
• 11 – Anthrax Vaccines*

  2018cites this paper
• Generation and screening of efficient neutralizing single domain antibodies (VHHs) against the critical functional domain of anthrax protective antigen (PA).

  2018cites this paper
• Controlled-Release Delivery Systems for Proteins and Peptides: A Third Generation Recombinant Vaccine-Delivery System for Single-dose Subcutaneous Administration

  2017cites this paper
• PEPTIDES : 3 RD-GENERATION INTRANASAL ANTHRAX VACCINE-DELIVERY SYSTEM “ The platform technology of this intranasal delivery system is also suitable for other human and veterinary vaccines including simultaneous intranasal delivery of multiple immunogens

  2017cites this paper
• Pharmacology and Anti-infective Role of Raxibacumab: A Novel Monoclonal Antibody for the Treatment of Anthrax.

  2016cites this paper
• Neurological Aspects of Biological and Chemical Terrorism

  2016cites this paper
• Bioterrorismo y atención primaria Grupo de Prevención en Enfermedades Infecciosas (PAPPS-semFYC) y Grupo de Enfermedades Infecciosas (semFYC)*

  2016cites this paper
• Production of Functionally Active and Immunogenic Non-Glycosylated Protective Antigen from Bacillus anthracis in Nicotiana benthamiana by Co-Expression with Peptide-N-Glycosidase F (PNGase F) of Flavobacterium meningosepticum

  2016cites this paper
• Biological Attack

  2015influential citation
• Evaluation of anthrax vaccine safety in 18 to 20 year olds: A first step towards age de-escalation studies in adolescents.

  2015cites this paper
• Intranasal immunization with protective antigen of Bacillus anthracis induces a long-term immunological memory response.

  2015cites this paper
• Anthrax Toxin Protective Antigen Forms an Unusual Channel That Unfolds and Translocates Proteins Across Membranes

  2015cites this paper
• Bacillus anthracis and Other Bacillus Species

  2015cites this paper
• The Bacillus anthracis Exosporium: What’s the Big “Hairy” Deal?

  2015cites this paper
• Electrophysiology of Unconventional Channels and Pores

  2015cites this paper
• Anthrax vaccine adsorbed: further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed.

  2014cites this paper
• Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.

  2013cites this paper
• 85 – Adverse Reactions to Vaccines for Infectious Diseases

  2013cites this paper
• Colonic Immune Stimulation by Targeted Oral Vaccine

  2013cites this paper
• 10 – Anthrax vaccines

  2013cites this paper
• Cost-Effectiveness Comparison of Response Strategies to a Large-Scale Anthrax Attack on the Chicago Metropolitan Area: Impact of Timing and Surge Capacity

  2012cites this paper
• Efficacy of a capsule conjugate vaccine against inhalational anthrax in rabbits and monkeys.

  2012cites this paper
• Characterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia.

  2012cites this paper
• Identification of novel and cross-species seroreactive proteins from Bacillus anthracis using a ligation-independent cloning-based, SOS-inducible expression system.

  2012cites this paper
• Vaccinology Is Turning into an Omics‐Based Science

  2012cites this paper
• Bioterrorism and Biodefense

  2012cites this paper
• A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice.

  2011cites this paper
• Anthrax bioterrorism: prevention, diagnosis and management strategies.

  2011cites this paper
• Finding Risk-Based Switchover Points for Response Decisions for Environmental Exposure to Bacillus anthracis

  2011cites this paper
• Anthrax Vaccine : Historical Review and Current Controversies

  2010cites this paper
• The Interactions between Bacillus anthracis and Macrophages

  2010cites this paper
• Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax

  2010cites this paper
• Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

  2010cites this paper
• Key roles of dendritic cells in lung infection and improving anthrax vaccines.

  2010cites this paper
• Raxibacumab for inhalational anthrax: an effective specific therapeutic approach?

  2010cites this paper
• Chapter 21 Medical Countermeasures Introduction Bacterial and Rickettsial Diseases Anthrax Tularemia Plague Glanders and Melioidosis Brucellosis Q Fever Virology Alphaviruses Smallpox Viral Hemorrhagic Fevers

  2009cites this paper
• Dr. Jekyll and Mr. Hyde: a short history of anthrax.

  2009cites this paper
• SENTETIK RESEPTÖRLERE DAYALI NANO ALGILAMA SISTEMLERI

  2009cites this paper
• Efficacy of a Vaccine Based on Protective Antigen and Killed Spores against Experimental Inhalational Anthrax (cid:1) ‡

  2009cites this paper
• Biologic Attack

  2009cites this paper
• Identification of B-cell epitopes on domain 4 of anthrax protective antigen

  2009cites this paper
• Raxibacumab for the treatment of inhalational anthrax.

  2009cites this paper
• Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses

  2009cites this paper
• Biological Agents and Terror Medicine

  2009cites this paper
• The Major Neutralizing Antibody Responses to Recombinant Anthrax Lethal and Edema Factors Are Directed to Non-Cross-Reactive Epitopes

  2009cites this paper
• Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.

  2009cites this paper
• Efficacy of recombinant anthrax vaccine against Bacillus anthracis aerosol spore challenge: preclinical evaluation in rabbits and Rhesus monkeys.

  2009cites this paper
• 12 Agents and Terror Medicine

  2009cites this paper
• Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis

  2009cites this paper
• Anthrax vaccination strategies.

  2009cites this paper
• Unanswered questions and ethical issues concerning US biodefence research

  2009cites this paper
• Bioterrorism

  2008cites this paper
• Infections émergentes ou ré-émergentes utilisables pour le bioterrorisme

  2008cites this paper
• Sequential B-Cell Epitopes of Bacillus anthracis Lethal Factor Bind Lethal Toxin-Neutralizing Antibodies

  2008cites this paper
• Biological Terrorism

  2008cites this paper
• Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel.

  2008cites this paper
• INTRODUCTION AND HISTORY THE ORGANISM EPIDEMIOLOGY PATHOGENESIS CLINICAL DISEASE Cutaneous Anthrax Inhalational Anthrax Oropharyngeal and Gastrointestinal Anthrax Meningitis DIAGNOSIS TREATMENT PROPHYLAXIS Prophylactic Treatment After Exposure Active Immunization Side Effects SUMMARY

  2008cites this paper
• Birth defects among infants born to women who received anthrax vaccine in pregnancy.

  2008cites this paper
• Attitudes toward predeployment and experimental vaccinations among troops deployed to Operation Iraqi Freedom and Operation Enduring Freedom.

  2008cites this paper
• Efficacy of a Vaccine Based on Protective Antigen and Killed Spores against Experimental Inhalational Anthrax

  2008cites this paper
• Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen.

  2008cites this paper
• Chemical Synthesis and Immunological Properties of Oligosaccharides Derived from the Vegetative Cell Wall of Bacillus anthracis

  2008cites this paper
• Analysis of a novel spore antigen in Bacillus anthracis that contributes to spore opsonization.

  2008cites this paper
• Vaccines: countering anthrax: vaccines and immunoglobulins.

  2008cites this paper
• Paratope diversity in the human antibody response to Bacillus anthracis protective antigen.

  2008cites this paper
• Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine.

  2007cites this paper
• Testing the Efficacy of a Combination of Microwave and Steam Heat for Log Reduction of the Microbial Load following a Simulated Poultry Mass Mortality Event

  2007cites this paper
• Multiple asparagine deamidation of Bacillus anthracis protective antigen causes charge isoforms whose complexity correlates with reduced biological activity

  2007cites this paper
• Responding to a small-scale bioterrorist anthrax attack: cost-effectiveness analysis comparing preattack vaccination with postattack antibiotic treatment and vaccination.

  2007cites this paper
• Transcriptional stimulation of anthrax toxin receptors by anthrax edema toxin and Bacillus anthracis Sterne spore.

  2007cites this paper
• Implications of Low Level Human Exposure to Respirable B. Anthracis

  2007cites this paper
• Catalytically inactive anthrax toxin(s) are potential prophylactic agents.

  2007cites this paper
• Countering Anthrax : Vaccines and Immunoglobulins

  2007cites this paper
• Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine.

  2007cites this paper
• Pathogenesis and sepsis caused by organisms potentially utilized as biologic weapons: opportunities for targeted intervention.

  2007cites this paper
• Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism

  2007cites this paper
• Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine

  2006cites this paper
• Risques bactériologiques

  2006cites this paper
• Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.

  2006cites this paper
• Immunogenicity and Protective Efficacy of Bacillus anthracis Poly-γ-d-glutamic Acid Capsule Covalently Coupled to a Protein Carrier Using a Novel Triazine-based Conjugation Strategy*

  2006cites this paper
• Recombinant Salmonella vaccines for biodefence.

  2006cites this paper
• N-fragment of edema factor as a candidate antigen for immunization against anthrax.

  2006cites this paper
• Recombinant viral-like particles of parvovirus B19 as antigen carriers of anthrax protective antigen.

  2006cites this paper
• Synthesis and antigenic analysis of the BclA glycoprotein oligosaccharide from the Bacillus anthracis exosporium.

  2006cites this paper
• Neurologists and the threat of bioterrorism.

  2006cites this paper
• Anthrax vaccines: Pasteur to the present.

  2006cites this paper
• Molecular basis for improved anthrax vaccines.

  2005cites this paper
• Cost-Effectiveness of Defending against Bioterrorism: A Comparison of Vaccination and Antibiotic Prophylaxis against Anthrax

  2005influential citation
• Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.

  2005cites this paper
• Chimeric Influenza Virus Hemagglutinin Proteins Containing Large Domains of the Bacillus anthracis Protective Antigen: Protein Characterization, Incorporation into Infectious Influenza Viruses, and Antigenicity

  2005cites this paper
• Identification of a Protein Subset of the Anthrax Spore Immunome in Humans Immunized with the Anthrax Vaccine Adsorbed Preparation

  2005cites this paper
• [Emerging or re-emerging infections that can be used for bioterrorism].

  2005cites this paper
• Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.

  2005cites this paper
• Negative attitude of highly educated parents and health care workers towards future vaccinations in the Dutch childhood vaccination program.

  2005cites this paper
• Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain.

  2005cites this paper